ViGeneron partners with WuXi for gene therapy manufacturing

By The Science Advisory Board staff writers

December 1, 2020 -- ViGeneron and WuXi Advanced Therapies have announced the formation of a strategic partnership to accelerate the clinical development of VG901, a next-generation ophthalmic gene therapy program.

ViGeneron's VG901 targets a disease gene for retinitis pigmentosa (RP), for which there are currently no approved treatment options. VG901 was developed using ViGeneron's proprietary vg adeno-associated virus (vgAAV) vector platform that allows superior transduction of retinal cells intravitreally, which is a less invasive treatment method.

As a contract testing, development, and manufacturing organization, WuXi will accelerate the development of VG901 by manufacturing, testing, and making available the clinical trial product, leveraging its AAV suspension and plasmid DNA platforms.

The companies plan to begin manufacturing by the end of 2020.

WuXi increases GMP plasmid DNA services
WuXi Advanced Therapies has expanded its cell and gene therapy platforms with capabilities to provide high-quality and cost-effective good manufacturing...
WuXi Biologics leases U.S. manufacturing facility
Hong Kong-based WuXi Biologics has signed a 10-year lease for a clinical manufacturing facility in Cranbury, NJ, making it the company's third site in...
WuXi to build manufacturing facility in U.S.
WuXi Biologics announced it has signed a deal with Worcester Business Development to build a clinical and commercial manufacturing facility in Worcester,...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter